IP Library › Granted Patent US 11,400,086
Granted Patent B2
US 11,400,086 · App. 16/482,547 · Granted Aug 2, 2022

Method of reducing chemotherapy-induced neutropenia

Inventors: Ramon Mohanlal (New York, NY); Lan Huang (New York, NY); George Kenneth Lloyd (San Carlos, CA)
Assignee: BeyondSpring Pharmaceuticals, Inc.
A61K31/496A61K31/337A61K38/193A61P35/00A61P37/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,400,086
App. No.
16/482,547
Granted
Aug 2, 2022
Kind
B2
Abstract

Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Claims (19)

1. A method of treating docetaxel-induced neutropenia in a subject, comprising administering a single dose of plinabulin in a 21-day docetaxel treatment cycle and administering one or more G-CSF drugs.

2. The method of claim 1 , wherein the amount of plinabulin in the single dose is greater than 1 mg/m 2 and less than 40 mg/m2.

3. The method of claim 1 , wherein the plinabulin is administered less than 1 hour after the administration of docetaxel.

4. The method of claim 1 , wherein the plinabulin is administered 10 minutes to 40 minutes after the administration of docetaxel.

5. A method of treating a Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) or Docetaxel and Cyclophosphamide (TC) chemotherapy-induced neutropenia in a subject, comprising administering a single dose of plinabulin in a 21-day treatment cycle and administering one or more G-CSF drugs.

6. The method of claim 5 , wherein the amount of plinabulin in the single dose is greater than 1 mg/m2 and less than 40 mg/m2.

7. The method of claim 5 , wherein the plinabulin is administered less than 1 hour after the administration of the TAC or TC chemotherapy.

8. The method of claim 1 , wherein the neutropenia is a grade 3 or 4 neutropenia.

9. The method of claim 1 , comprising reducing an incidence of grade 4 neutropenia by at least 5%.

10. The method of claim 1 , comprising reducing a duration of grade 4 neutropenia by at least 2 times.

11. A method of treating a chemotherapy induced neutropenia, comprising administering a single dose of plinabulin in a chemotherapy treatment cycle within 2 hours after the administration of the chemotherapy and administering one or more G-CSF drugs, wherein the dose of the G-CSF drug is in the range of 1 mg to 10 mg.

12. The method of claim 11 , wherein the G-CSF drug is pegfilgrastim.

13. The method of claim 11 , comprising administering the GCSF drug at least 24 hours after the administration of the chemotherapy.

14. The method of claim 11 , comprising administering a single dose of plinabulin in a 21-day treatment cycle.

15. The method of claim 11 , comprising administering plinabulin at a dose in the range of 1 mg/m 2 to 50 mg/m2.

16. The method of claim 1 , wherein the patient has an advanced or metastatic breast cancer, early breast cancer, non-small cell lung cancer, or refractory metastatic prostate cancer.

17. The method of claim 1 , wherein administering one or more G-CSF drugs is administered in a dose in a range from of 3 mg to 6 mg.

18. The method of claim 5 , wherein administering one or more G-CSF drug is administered in a dose in a range from of 3 mg to 6 mg.

19. The method of claim 11 , wherein the dose of the G-CSF drug is in a range from of 3 mg to 6 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2019
From: MOHANLAL, RAMON; HUANG, LAN; LLOYD, GEORGE KENNETH
To: BEYONDSPRING PHARMACEUTICALS, INC.
Reel/Frame 049979/0676 →
Continuity (3)
Provisional Application 62621533 · Jan 24, 2018
Provisional Application 62453375 · Feb 1, 2017
Related Publication 20200038395A1 · Feb 6, 2020
Cited By (4)
US 12,377,094 US 12,433,886 US 12,458,638 US 12,458,639